- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
CLDX Market Currents
more »
-
Thursday 9:05 AM Premarket gainers: KUTV +34%. P +19%. CLDX +9%. HPQ +8%. GALE +6%.
Losers: MNOV -52%. NTAP -13%. SIG -9%. TIF -8%.Comment![On the Move] - Wednesday 5:12 PM Celldex Therapeutics (CLDX) takes a hit in the post session after releasing mixed preliminary results from randomized Phase 2b tests of CDX-011 antibody drug conjugate in patients with advanced, heavily pretreated breast cancer. Shares -8.5% AH. [Healthcare]
CLDX in Focus
more »
CLDX Related Articles
more »
CLDX News
more »
-
at MarketWatch.com (Thu, 3:23PM)
-
at MarketWatch.com (Feb 24, 2012)
-
at MarketWatch.com (May 18, 2011)
-
at MarketWatch.com (May 18, 2011)
-
at MarketWatch.com (Oct 6, 2010)
CLDX Press Releases and Filings
more »
-
Business Wire (Wed, 4:01PM)
-
Business Wire (May 18, 2012)
-
Business Wire (May 15, 2012)
-
Business Wire (May 3, 2012)
-
Business Wire (May 1, 2012)
CLDX Latest Transcript
more »
Currently, there are no transcripts for CLDX.
CLDX Cramer
more »
Currently, there are no Cramer articles on CLDX.
CLDX Instablog posts
more »
CLDX vs. ETF Alternatives
Company Description
Celldex is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of... More
